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Abstract: Average blood loss after total knee arthroplasty (TKA) usually ranges from 1500 to 1900 cc, including both the 
postoperative drain and hidden blood loss. This represents about 46% of TKA patients requiring postoperative blood 
transfusion. Not only the risks of disease transmission but also those of ABO incompatibility, infection due to 
immunosupression, increased procedure costs, and increased length of hospital stay, are potential problems that foster 
blood saving strategies. In this study, 71 unilateral TKAs using a multimodal protocol to decrease blood loss were 
compared to 61 historical cases. Patients in both groups underwent cemented TKA with the same system, surgical 
technique, and multimodal protocol (MIS approach, plug in the femoral canal, tourniquet removal after wound closure and 
compressive bandage, analgesic periarticular infiltration with vasoconstrictor, postoperative drain at atmospheric pressure, 
opened 2 hours after the end of the surgical procedure and removed after 24 hours). The study series incorporated 
intravenous tranexamic acid (TXA) infusion in 2 doses of 10-15 mg/kg, 15 minutes before tourniquet release and 3 hours 
later. Results showed no transfusion requirements in the TXA series (0%), with 23/61 (37.7%) transfusions in the control, 
with an average cost decrease of 240 euros per patient. Visible bleeding in 24h significantly decreased from 553.36 cc 
(range 50-1500) to 169.72 cc (range 10-480) in the TXA series. As a conclusion, implementing a TXA-based multimodal 
protocol produced significant decrease in the transfusion rate, visible blood loss, and cost per patient, thus proving 
effectiveness and efficiency in the surgical management of TKA. 
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INTRODUCTION 
  Current surgical technique in total knee arthroplasty 
(TKA) usually includes the use of tourniquet, resulting in 
unapparent intraoperative bleeding but substantial 
postoperative blood loss. Postoperative drainage ranges 500 
to 1000 cc, with additional hidden blood loss up to 700 cc 
[1]. Therefore, total blood loss is calculated, based on pre 
and postoperative hematocrit values, within a range of 1500 
to 1900 cc [2]. Blood loss in TKA patients is multifactorial. 
Ischemia increases fibrinolysis, related to the proteolytic 
action of plasmin, with subsequent fibrinogen scission which 
limits postoperative coagulation and favors bleeding [3-5]. 
Factors that may influence bleeding after TKA include 
patient co-morbidities (cardiovascular, respiratory diseases, 
hepatic and coagulation disorders), medication (NSAIDs, 
salicilates, LMWH, antiagregants), anesthesia (spinal versus 
general), postoperative control of blood pressure (systolic 
under 150 mmHg), surgical technique (use of cement, 
incision, tourniquet time, haemostasia, tissue damage). 
  Allogenic blood transfusion associates the currently 
decreased risk of infectious disease transmission. Some of 
these cannot be detected by the laboratory (Chagas disease,  
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Lyme disease, malaria, prion-mediated diseases), while 
others support a quantified risk, ranging from VHC 
(0.8/million), HIV (0.14/million), VHB (1.66/million), to 
bacterial contamination (2/million) [2, 6, 7]. Besides, 
iatrogenic severe error due to ABO discrepancy is also a 
potential risk, ranging from 1/400 units in Belgium or 1/3400 
in France, to 1/36000 units in Germany [8]. Allogenic blood 
transfusion in Europe was evaluated in a multicentric study 
after hip and knee unilateral replacement surgery on 3996 
patients, and 46% transfusions were required, in correlation 
with low preoperative hemoglobin. Infection rate in those 
patients raised to 4%, compared with 1% in case of auto-
logous transfusion [9], possibly related to immunodepresion 
associated with allogenic transfusion [9, 10]. 
  The mentioned risks, including increased morbidity and 
longer Hospital stays, but also refusals due to religious 
beliefs (as in the case of Jehovah’s witnesses [11]) justify 
clinical strategies to minimize exposure to allogenic blood 
transfusion. As hyperfibrinolysis is considered the major 
cause of postoperative bleeding after TKA surgery [3, 4, 12-
14], antifibronolytic  drugs have been proposed, including 
aprotin, aminocaproic acid, and tranexamic acid. Aprotin, 
derived from bovine lung, inhibits the serinprotease at the 
last stage of fibrinolysis, but allergies, thrombosis, 
nephrotoxicity, and spongiform encephalopathy [6] lead this 
drug out of the Spanish market. Aminocaproic acid is less 
effective, more expensive and less supported by the literature 
than tranexamic acid [3, 15]. Tranexamic acid (TXA) is a Blood Loss Control with Two Doses of Tranexamic Acid  The Open Orthopaedics Journal, 2011, Volume 5    45 
synthetic analog of serin than reversibly inhibits fibrinolysis 
by blocking lysine union sites in the plasmin and 
plasminogen activator molecules. It has been used during 
more than 20 years in cardiac surgery, urology, ginecology, 
liver transplants, etc. 
  In this context, the aim of our study was to compare 
transfusion rate, postoperative bleeding, and additional costs, 
in a consecutive cohort of patients under a multimodal blood 
saving protocol using tranexamic acid, with a historical 
consecutive cohort in the same settings. 
PATIENTS AND METHOD 
  A cohort of 71 consecutive patients (study group) with 
unilateral TKA was prospectively studied. These patients 
received 2 doses of tranexamic acid (Amchafibrin, 
Rottapharm, S.A. Barcelona, Spain). A first dose of 
15mgr/kg weight in 100cc saline was slowly infused in 15-
20 minutes, before tourniquet release. A second identical 
dose was administered after 3 hours. In a case-control study, 
this group was compared with a consecutive series of 61 
patients that underwent TKA before the clinical protocol was 
introduced. Surgical technique, pre- and postoperative 
management, and transfusion criteria were the same between 
both series. Both series included patients in the same 
geographic area (North Madrid, Spain), and underwent 
surgery by the same group of experienced surgeons and 
anesthesiologists, with special dedication to this surgery. 
Variables under comparison included hematocrit and 
hemoglobin determinations, visible blood loss, transfusion 
requirements, and additional costs generated by transfusion. 
This observational study was approved by the local ethical 
committee and all the patients signed the informed consent. 
  Surgeries in the studied series with tranexamic acid were 
performed between October 2008 and May 2009, and the 
control series was included in the prior 6 months. Exclusion 
criteria were previous thromboembolic disease, previous 
myocardium infarct, hematologic disease, and retinopathy. 
Four patients were excluded in the study period. Anesthesia 
in all cases was hyperbaric intradural with 0.5% bupivacaine, 
fentanyl, and continuous IV infusion of midazolam and/or 
propofol. Ischemia was performed with pneumatic 
tourniquet at 100mmHg above systolic arterial pressure. 
Limited anterior incision followed by parapatelar medial 
approach without patellar eversion and minimally invasive 
surgical instrumentation were used in all cases. The 
technique included cemented posterostabilized NexGen® 
(Zimmer, Warsaw, Indiana, USA) prosthesis with systematic 
patellar replacement, except in 3 cases of the TXA group that 
received a non cemented NexGen® prosthesis with tantalium 
in the tibial and titanium mesh in the femoral component. 
Cement in use was Palacos R+G (Heraeus Medical, Hanau, 
Germany), and autologous bone was used to fill the drill of 
the intramedullary guide into the femoral canal before 
cementing. All cases underwent a multimodal analgesia 
protocol, as well as intra- and periarticular injection of 80cc 
of saline with adrenalin 300gr, morphic chloride 10mgr, 
tobramicin 100mgr, betametasone sodic phosphate 6mgr, 
betametasone acetate 6mgr, ropivacaine 200mgr (30cc in the 
posterior capsule, collateral ligaments, and medial wall   
 
before cementing, 50cc in the arthrotomy after closure and 
intraarticularly). One single intraarticular drain (Drenofast 
CH-12/4,0 min Iberhospitex, S.A. Barcelona, Spain) was 
used per surgery, at atmospheric pressure without vacuum, 
opened one hour after closure and systematically retrieved 
after 24 hours. Tourniquet release occurred after wound 
closure and knee bandage in all cases. Antithromboembolic 
prophylaxis in both groups was performed with enoxaparin 
(Clexane 40mg, laboratorio Sanofi-Aventis, S.A., Barcelona, 
Spain), 40 mgr via subcutaneous injection during 3 weeks. 
Antibiotic prophylaxis included cephalosporin 2gr 1 hour 
before surgery and 1gr/8h during 48 hours. In allergic 
patients, vancomicin 1gr pre and 1gr/12h postop were used. 
  Transfusion was decided in both groups by the 
Orthopaedic surgeon and/or Anesthesiologist on call. As a 
general rule, hemoglobin laboratory determination under 8.0 
gr/dL and/or related symptoms of acute anemia required 
transfusion, whereas in patients with cardiovascular or 
pulmonary comorbidities, the threshold was set at 9.0 gr/dL. 
Repeated laboratory tests including both hematocrit and 
hemoglobin determination were performed preoperatively 
and postoperatively in the recovery unit, and days 1 and 2). 
The direct cost of a single unit of red cell concentrate in our 
Hospital was 300 euros. The direct cost of the administered 
TXA was 3.05 euros. 
  In the statistical analysis, quantitative variables are 
expressed as mean and standard deviation, and qualitative 
variables by absolute and relative frequencies. The 
quantitative variables were compared with Student’s t-test, 
when Kolmogorov-Smirnov test confirmed the normal 
distribution. The comparison of qualitative variables was 
performed by Chi-square and Fisher’s exact test. The 
sequential evolution of hematocrit and hemoglobin 
determinations was analyzed by two-factor ANOVA for 
repeated measurements. Differences between groups in 
evolution profiles were also evaluated. Bonferroni post-hoc 
test was used when required. SPSS 15.0 was used as 
statistical software (SPSS Inc., Chicago IL). 
RESULTS 
  Both study groups were similar, with no statistically 
significant differences in demographics, surgical variables, 
and preoperative laboratory parameters, as seen in Table 1. 
Statistically significant differences were found in the amount 
of visible bleeding at the drain in 24h, and in the percentage 
of transfused patients (Table 2), with significantly less 
bleeding and less transfused patients in the TXA group (Fig. 
1). While no patients received transfusion in the group 
treated with tranexamic acid, 23 out of 61 patients required 
transfusion in the control group (37.7%), 2 of which received 
pre-donated autologous blood. These 23 patients consumed 
in total 49 units of concentrated red cells, 4 of them requiring 
1 unit, 14 required 2 units, 4 required 3 units and one patient 
required 5 units. 
  Hemoglobin and hematocrit evolution in the 48h of 
observation was significantly different between the two 
groups (p=0.001). The studied values decreased more in the 
control group (Table 3) than in the TXA group (Table 4), 
even if the control group received an average of 0.8 units of 
concentrated red cells. 
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Fig. (1). Box plot (mean and error bars of standard deviation) of 24-
hour drainage for both groups in the study: the group with tranexamic 
acid (n=71 patients) and the control group (n=61 patients). 
  The cost of one single unit of red cells in our Hospital being 
300 euros, the total cost of red cell units for the control series 
was 14.700 euros. Because an average of 0.8 units was 
transfused per patient in the control, the average direct cost per 
patient was 240 euros. 
  Special care was taken in the diagnosis of deep venous 
thrombosis (DVT). Patients with clinical signs of calf 
circumference increase underwent venous eco-doppler 
performed by an experienced vascular radiologist. This was 
required in 7 patients of the control group and 3 in the TXA 
group. In all of them, the deep venous system was permeable. 
Nevertheless, these patients received one month treatment of 
low-molecular weight heparin at therapeutic dosage. No patient 
presented with pulmonary embolism. One patient in the control 
group suffered from deep periprosthetic infection by S. aureus 4 
months after surgery, and required two-stage revision surgery. 
Two patients in the study group underwent intense nausea 
related to tranexamic acid infusion in less than 15 minutes. Slow 
infusion (more than 15 minutes) of tranexamic acid is required 
to avoid this complication. 
DISCUSSION 
  Different strategies have been established to decrease the 
risk of allogenic blood transfusion in the postoperative patient. 
In our study, we significantly decreased the risk of allogenic 
blood transfusion through a protocol that included two doses of 
tranexamic acid. Other techniques include predonation, blood 
recovery, preoperative treatments, or hemodilution. 
  Preoperative autologous blood donation followed by 
autotransfusion is an expensive procedure with logistic 
problems in many Hospitals. Furthermore, about 45% 
predonated units may be discarded due to different reasons [10]. 
Some authors recommend at least 50% transfusion to support a 
predonation program [16]. Postoperative blood recovery and 
reinfusion is an equivalent of autologous donation [2, 17]. As 
the risk of transfusion depends on the preoperative hemoglobin 
values, preoperative treatments such as eritropoietin and 
intravenous iron have been proposed to avoid postoperative 
transfusion [15, 16]. Patients with anemia (preoperative 
hemoglobin under 12 g/dL) could benefit, but with a raise in the 
procedure cost (in our setting, 3000 euros if 3 doses are 
prescribed per patient). Normovolemic hemodilution has been 
also proposed [18], consisting on the collection of 1-2 blood 
Table 1.  Demographics and Surgical Variables in Both Studied Groups of Patients (Mean (Range); p Values After Statistical 
Comparison, Student t-Test or Fischer’s Exact Test) 
 
  Control Group (N = 61)  Tranexamic Acid Treatment Group (N = 71)  p Value 
Age (years)  69 (52-82)  71 (53-85)  p=0.144 
Sex ratio: women/men  43/18  55/16  p=0.426 
Weight (kg)  78.07 (53-118)  76.69 (53-108)  p=0.486 
ASA I 
ASA II 
ASA III 
2 
37 
22 
1 
47 
23 
p=0.639 
Tourniquet time   86.2 minutes (55-120)  92.2 minutes (65-120)  p=0.350 
Cemented implants  61 cemented  68 cemented/3 non-cemented   
Preoperative hematocrit (%)  42.3 (34.1 -51.9)  43.0 (31.9 - 50.5)  p=0.294 
Preoperative hemoglobin (g/dL)  14.4 (11.9 - 17.9)  14.3 (10.6 -17.2)  p=0.642 
ASA = American Society of Anaesthesiology Status. 
 
Table 2.  Outcome Variables in Both Studied Groups of Patients (Mean (Range); p Values After Statistical Comparison, Student t-
Test or Fischer’s Exact Test) 
 
  Control Group (N=61)  Tranexamic Acid Treatment Group (N=71)  p Value 
Bleeding in 24h drain (cc)  553.36 (50-1500)  169.72 (10-480)  p=0.001 
Transfusion (% patients)  23 patients (37.7%)  0 patients (0%)  p=0.001 Blood Loss Control with Two Doses of Tranexamic Acid  The Open Orthopaedics Journal, 2011, Volume 5    47 
units during surgery and reinfusion when hematocrit decreases 
under 28%. Criticisms include those of reinfusion from blood 
cell recovery programs, variable patient tolerance, and 
unnecessary blood collection in those patients not requiring 
postoperative transfusion, with subsequent discard of these 
units. 
  Multiple surgical variables may affect postoperative blood 
loss, and although isolated surgical gestures may represent 
limited savings, the simultaneous use of these techniques may 
produce a substantial blood loss reduction. Tourniquet release 
after wound closure and bandage proved blood loss decrease in 
many studies [19-21]. A meta-analysis including 11 prospective 
randomized trials concluded that tourniquet release to perform 
surgical hemostasis before closure was related to an increased 
bleeding of 229cc in average [20]. Limited incision with 
minimally invasive surgery technique (MIS) was also associated 
to a decreased blood loss and hospital length of stay [22, 23]. 
Plugging the intramedullary canal of the femur after 
introduction of the intramedullary instrumentation guide 
significantly reduced blood loss in TKR up to 17% [24]. Intra- 
and peri-articular local infiltration to postoperatively control 
pain, associating vasoconstrictor medication, also reduced blood 
loss [25, 26]. Blood loss decreased in all-component cemented 
TKR due to the hemostatic effect of cement polymerization on 
the exposed bone [27]. The use of drainage raised the 
transfusion rate in a meta-analysis of 18 prospective randomized 
controlled trials [28, 29]. Not using drains did not raise the 
infection rate or local wound complications [28, 29]. In our 
study, we just used one single atmospheric pressure drainage 
system during 24h, and the drainage opening was delayed one 
hour after surgery. Also, our transfusion rate in unilateral, 
cemented primary TKR was 48%, and decreased to 37.7% after 
using the limited approach with MIS technique, and the 
vasoconstrictor in the multimodal postoperative analgesia 
protocol. 
  Although tourniquet decreases TKR intraoperative bleeding, 
postoperative blood loss occurs due to an increased fibrinolysis 
in response to exanguination [5, 13, 30, 31]. Tranexamic acid 
inhibits fibrinolysis through a reversible molecular block of 
lysine union sites in the plasmin, plasminogen, and tissue 
activator of plasminogen. This antifibrinolytic molecule is 10 
times more effective than aminocaproic acid. Effective 
plasmatic levels are reached 10-15 minutes after infusion, and 
therapeutic level must be maintained at tourniquet release, being 
the initial dose administration crucial to efficacy [3-5, 13, 14, 
30]. Safety was also a matter of concern regarding the possible 
thrombogenic effect with the use of tranexamic acid, but this 
was not found in different studies [3-5, 30, 31]. A meta-analysis 
of 8 randomized studies comparing with placebo concluded that 
TXA use is effective in decreasing allogenic blood transfusion 
requirements without increasing the thrombosis rate in TKR [3]. 
Effectiveness is also a matter of controversy, as more recent 
randomized clinical trials proved a significant early 
postoperative decrease in blood loss, but one single TXA dose 
failed to confirm a significant association with total blood loss 
or transfusion requirements [32]. Meanwhile, other authors also 
used one single intraoperative dose of TXA and reduced 
transfusion rates [33]. In a recent systematic review of 
randomized trials [34], the use of antifibrynolytic agents to 
reduce bleeding and transfusion risk to a 50%, without 
increasing thromboembolic risk, is well proven. More debate 
persists on the dosage and timing of administration, and 
heterogeneity limits the strength of conclusions on these aspects 
in the mentioned systematic review [34], this debate justifying 
further studies to maximize effectiveness. In our experience, a 
multimodal protocol with tranexamic acid administration in two 
doses of 15mg/kg, the first dose infused 15-20 minutes before 
tourniquet release, and repeated after 3 hours, virtually revoked 
the need of transfusion in our series, from a rate of 37.7% in the 
control group to 0% in the treatment group, while the visible 
bleeding in the 24h drainage also decreases from 553.3 cc in the 
control group to 169.7cc in the treatment group. Our conjoined 
strategy shows notable results in restricting transfusion 
requirements, and its use is simple and safe, not increasing 
thromboembolic complications in our hands. Saving an average 
of 0.8 concentrated blood cell units per patient represented 
direct cost savings of 240 euros per procedure in our settings, 
not considering the indirect savings related to allogenic 
transfusion risks and derived expenditure. 
  The results of this multimodal protocol allowed us to 
incorporate primary, unilateral TKR procedures without blood 
transfusion into our offer of services as a provider, giving an 
Table 3.  Blood Loss Evolution (48 h) in the Control Group (without Tranexamic Acid), n=61 Patients 
 
  Preoperative  6 h  24 h  48 h 
Hemoglobin g/dL 
14.4 
(11.9 - 17.9) 
12.2 
(9.0 - 14.1) 
10.9 
(7.5 - 13.3) 
10.3 
(7.4 - 12.8) 
Hematrocrit % 
42.3 
(34.1 -51.9) 
36.3 
(27.3 -41.8) 
32.0 
(24 - 42.6) 
30.7 
(25.3 -36.1) 
 
Table 4.  Blood Loss Evolution (48 h) in the Tranexamic Acid Group, n=71 Patients 
 
  Preoperative  6 h  24 h  48 h 
Hemoglobin g/dL 
14.3 
(10.6 -17.2) 
12.7 
(9.7 - 15.1) 
12.1 
(8.9 - 12.8) 
11.3 
(8.7 - 12.0) 
Hematrocrit % 
43.0 
(31.9 - 50.5) 
38.0 
(29.0 -42.3) 
36.3 
(25.9 -37.8) 
33.7 
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increased demand by Jehova’s witnesses and other groups of 
patients. Based on this study, we can conclude that two-dose IV 
tranexamic acid, in a multimodal protocol, can be used in TKR 
procedures with proven effectiveness and efficiency to decrease 
postoperative blood loss in our patients undergoing TKR. 
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